Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of α4β2 nicotinic receptors in rats

Neuropharmacology

Volumn 57, Issue 1, 2009, Pages 60-66

  Spiller, Krista ^a   Xi, Zheng Xiong ^a   Li, Xia ^a   Ashby Jr , Charles R ^b   Callahan, Patrick M ^c   Tehim, Ashok ^c   Gardner, Eliot L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c Memory Pharmaceuticals Corporation   (United States)

Author keywords

4 2 receptors; Addiction; Dopamine; Nicotine; Reward; Varenicline

Indexed keywords

BUNGAROTOXIN RECEPTOR; NICOTINE; NICOTINIC RECEPTOR ALPHA4BETA2; VARENICLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DEPTH STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; SMOKING CESSATION; SYSTEMIC THERAPY; TOBACCO DEPENDENCE;

ANIMALS; BENZAZEPINES; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTRIC STIMULATION; MALE; MEDIAL FOREBRAIN BUNDLE; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; QUINOXALINES; RATS; RATS, LONG-EVANS; RECEPTORS, NICOTINIC; REWARD;

EID: 67349178261     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.04.006     Document Type: Article

References (57)

1. Bozarth M.A., Pudiak C.M., and KuoLee R. Effect of chronic nicotine on brain stimulation reward. I. Effect of daily injections. Behav. Brain Res. 96 (1998) 185-188
2. Brioni J.D., Kim D.J.B., and O'Neill A.B. Nicotine cue: lack of effect of the alpha7 nicotinic receptor antagonist methyllycaconitine. Eur. J. Pharmacol. 301 (1996) 1-5
3. 3H]dopamine release. Neuropharmacology 48 (2005) 72-79
4. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48 (2005) 3474-3477
5. Cooper E., Couturier S., and Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal acetylcholine receptor. Nature 350 (1991) 235-238
6. Couturier S., Bertrand D., Matter J.-M., Hernandez M.-C., Bertrand S., Millar N., Valera S., Barkas T., and Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (α7) is developmentally regulated and forms a homo-oligomeric channel blocked by α-BTX. Neuron 5 (1990) 847-856
7. Cryan J.F., Bruijnzeel A.W., Skjei K.L., and Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168 (2003) 347-358
8. Foulds J. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int. J. Clin. Pract. 60 (2006) 571-576
9. Fudala P.J., and Iwamoto E.T. Further studies on nicotine-induced conditioned place preference in the rat. Pharmacol. Biochem. Behav. 25 (1986) 1041-1049
10. Fudala P.J., Teoh K.W., and Iwamoto E.T. Pharmacologic characterization of nicotine-induced conditioned place preference. Pharmacol. Biochem. Behav. 22 (1985) 237-241
11. Goldberg S.R., Spealman R.D., and Goldberg D.M. Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214 (1981) 573-575
12. Gommans J., Stolerman I.P., and Shoaib M. Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 39 (2000) 2840-2847
13. Gordon J., Gurley D.A., Tran O., Machulskis A., Zongrone J., et al. AR-R 17779: the first high affinity, subtype-selective full agonist at the rodent α7 nicotinic acetylcholine receptor. Soc. Neurosci. Abstr. 24 (1998) 331.9
14. Gotti C., Riganti L., Vailati S., and Clementi F. Brain neuronal nicotinic receptors as new targets for drug discovery. Curr. Pharm. Des. 12 (2006) 407-428
15. Grady S.R., Meinerz N.M., Cao J., Reynolds A.M., Picciotto M.R., Changeux J.-P., McIntosh J.M., Marks M.J., and Collins A.C. Nicotinic agonists stimulate acetylcholine release from mouse interpeduncular nucleus: a function mediated by a different nAChR than dopamine release from striatum. J. Neurochem. 76 (2001) 258-268
16. Gurley D.A., Lanthorn T., Ryan T., Luhowskyj S., and Gordon J. Comparison of nicotine and the α7-selective agonist AR-R 17779 on nAchR α7 expressed in Xenopus oocytes. Soc. Neurosci. Abstr. 24 (1998) 331.10
17. Harvey S.C., and Maddox F.N. Multiple determinants of dihydro-β-erythroidine sensitivity on rat neuronal nicotinic receptor α subunits. J. Neurochem. 67 (1996) 1953-1959
18. Huston-Lyons D., and Kornetsky C. Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacol. Biochem. Behav. 41 (1992) 755-759
19. Khiroug S.S., Khiroug L., and Yakel J.L. Rat nicotinic acetylcholine receptor α2β2 channels: comparison of functional properties with α4β2 channels in Xenopus oocytes. Neuroscience 124 (2004) 817-822
20. Klink R., de kerchove, d'Exacrde A., Zoli M., and Changeux J. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J. Neurosci. 21 (2001) 1452-1463
21. Lambe E.K., Picciotto M.R., and Aghajanian G.K. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 28 (2003) 216-225
22. Laviolette S.R., and van der Kooy D. The motivational valence of nicotine in the rat ventral tegmental area is switched from rewarding to aversive following blockade of the α7-subunit-containing nicotinic acetylcholine receptor. Psychopharmacology 166 (2003) 306-313
23. Le Novère N., Corringer P.-J., and Changeux J.-P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J. Neurobiol. 53 (2002) 447-456
24. Markou A. Neurobiology of nicotine dependence. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363 (2008) 3159-3168
25. Marks M.J., Pauly J.R., Gross S.D., Deneris E.S., Hermans-Borgmeyer I., Heinemann S.F., and Collins A.C. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci. 12 (1992) 2765-2784
26. Marubio L.M., Gardier A.M., Durier S., David D., Klink R., Arroyo-Jimenez M.M., McIntosh J.M., Rossi F., Champtiaux N., Zoli M., and Changeux J.-P. Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur. J. Neurosci. 17 (2003) 1329-1337
27. Maskos U., Molles B.E., Pons S., Besson M., Guiard B.P., et al. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436 (2005) 103-107
28. Menzaghi F., Whelan K.T., Risbrough V.B., Rao T.S., and Lloyd G.K. Effects of a novel cholinergic ion channel agonist SIB1765F on locomotor activity in rats. J. Pharmacol. Exp. Ther. 280 (1997) 384-392
29. Mihalak K.B., Carroll F.I., and Luetje C.W. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Mol. Pharmacol. 70 (2006) 801-805
30. 3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int. J. Neuropsychopharmacol. 9 (2006) 585-602
31. Paterson N.E., Balfour D.J., and Markou A. Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. Nicotine Tob. Res. 10 (2008) 995-1008
32. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. fourth ed. (1998), Academic Press, San Diego, CA
33. Picciotto M.R. Nicotine as a modulator of behavior: beyond the inverted U. Trends Pharmacol. Sci. 23 (2003) 494-499
34. Picciotto M.R., Zoli M., Rimondini R., Léna C., Marubio L.M., Merlo Pich E., Fuxe K., and Changeux J.-P. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998) 173-177
35. Picciotto M.R., Caldarone B.J., Brunzell D.H., Zachariou V., Stevens T.R., and King S.L. Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol. Ther. 92 (2001) 89-108
36. 2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52 (2007) 985-994
37. Rollema H., Coe J.W., Chambers L.K., Hurst R.S., Stahl S.M., and Williams K.E. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol. Sci. 28 (2007) 316-325
38. Romanelli M.N., and Gualtieri F. Cholinergic nicotinic receptors: competitive ligands, allosteric modulators, and their potential applications. Med. Res. Rev. 23 (2003) 393-426
39. Sacaan I., Reid R.T., Santori E.M., Addmas P., Correa L.D., et al. Pharmacological characterisation of SIB-1765F: a novel cholinergic ion channel agonist. J. Pharmacol. Exp. Ther. 280 (1997) 373-383
40. Salminen O., Murphy K.L., McIntosh M., Drago J., Marks M.J., Collins A.C., and Grady S.R. Submit composition and pharamacology of two classes of striatal presynaptic nicotinic acetycholine receptors mediating dopamine release in mice. Mol. Pharmacol 65 (2004) 1526-1535
41. Shoaib M., Gommans J., Morley A., Stolerman I.P., Grailhe R., and Changeux J.P. The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion. Neuropharmacology 42 (2002) 530-539
42. Smith J., Mogg A.M., Tafi E., Peacey E., Pullar I.A., Szekeres P., and Tricklebank M. Ligands selective for α4β2 but not α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology 190 (2007) 157-170
43. 3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats. Psychopharmacology 196 (2008) 533-542
44. Steensland P., Simms J.A., Holgate J., Richards J.K., and Bartlett S.E. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 12518-12523
45. Stolerman I.P., Chamberlain S., Bizarro L., Fernandes C., and Schalkwyk L. The role of nicotinic receptor α7 subunits in nicotine discrimination. Neuropharmacology 46 (2004) 363-371
46. Tapper A.R., McKinney S.L., Nashmi R., Schwarz J., Deshpande P., Labarca C., Whiteaker P., Marks M.J., Collins A.C., and Lester H.A. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306 (2004) 1029-1032
47. Tutka P. Nicotine receptor partial agonists as novel compounds for the treatment of smoking cessation. Expert Opin. Investig. Drugs 17 (2008) 1473-1485
48. Van Kampen M., Selbach K., Schneider R., Schiegel E., Boess F., and Schreiber R. AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology 172 (2004) 375-383
49. Watkins S.S., Epping-Jordan M.P., Koob G.F., and Markou A. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol. Biochem. Behav. 62 (1999) 743-751
50. Watkins S.S., Koob G.F., and Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob. Res. 2 (2000) 19-37
51. Williams M., and Robinson J.L. Binding of the nicotinic cholinergic antagonist, dihydro-β-erythroidine, to rat brain tissue. J. Neurosci. 4 (1984) 2906-2911
52. Wise R.A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 19 (1996) 319-340
53. Wu J., George A.A., Schroeder K.M., Xu L., Marxer-Miller S., Lucero L., and Lukas R.J. Electrophysiological, pharmacological and molecular evidence for α7-nicotinic acetylcholine receptors in rat midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 311 (2004) 80-91
54. Xi, Z-X., Spiller, K., Gardner, E.L. Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol. Sinica, in press.
55. Zhu P.J., and Chiappinelli V.A. Nicotinic receptors mediate increased GABA release in brain through a tetrodotoxin-insensitive mechanism during prolonged exposure to nicotine. Neuroscience 115 (2002) 137-144
56. Zierler-Brown S.L., and Kyle J.A. Oral varenicline for smoking cessation. Ann. Pharmacother. 41 (2007) 95-99
57. Zoli M., Léna C., Picciotto M.R., and Changeux J.-P. Identification of four classes of brain nicotinic receptors using β2 mutant mice. J. Neurosci. 18 (1998) 4461-4472